Table 4.
Drug combinations with non-approved epigenetic agents in B-NHL.
| Epigenetic drug class | Drug | Agent used in combination | Trial identifier |
|---|---|---|---|
| HDAC inhibitor | CUDC-907 | Rituximab, venetoclax, and bendamustine | NCT01742988 |
| Entinostat | Isotretinoin | NCT00098891 | |
| Molibresib | NCT03925428 | ||
| Mocetinostat | Azacitidine | NCT00543582 | |
| EZH2 inhibitor | Tazemetostat | Fluconazole, omeprazole, and repaglinide | NCT03028103 |
| Atezolizumab and obinutuzumab | NCT02220842 | ||
| Prednisolone | NCT01897571 | ||
| PF 06821497 | SOC | NCT03460977 | |
| BET inhibitor | Molibresib | Entinostat | NCT03925428 |
| RO6870810 | Venetoclax and rituximab | NCT03255096 | |
| INCB057643 | Gemcitabine, paclitaxel, rucaparib, abiraterone, ruxolitinib, and azacitidine | NCT02711137 | |
| FT-1101 | Azacitidine | NCT02543879 |
Source: https://clinicaltrials.gov/.